Breast Cancer – Unmet Need – Unmet Need – Advanced or Metastatic HER2-Positive Breast Cancer (US/EU)

In the last decades, markedly improved survival benefit has been achieved in the treatment of advanced or metastatic HER2-positive breast cancer. Effective HER2-targeted drugs such as Herceptin, Perjeta, and Kadcyla (all from Roche / Genentech) have greatly contributed to these outcomes. More recently, the second-generation HER2-targeted antibody drug conjugate Enhertu (AstraZeneca / Daiichi Sankyo) was added to the treatment armamentarium after showing unprecedented improvement in efficacy in the refractory setting. Enhertu, along with recently approved novel tyrosine kinase inhibitors such as Tukysa (Pfizer), are rapidly changing the treatment paradigm of this disease. While current therapies are highly effective in disease control, significant clinical opportunity remains for drug developers to overcome resistance to HER2-targeted agents and to limit associated drug toxicity.

Questions answered

• How satisfied are U.S. and European medical oncologists with the current treatment options for metastatic HER2-positive breast cancer?
• What are the treatment drivers and goals in medical oncologists’ prescribing decisions in metastatic HER2-positive breast cancer? How do current therapies, such as AstraZeneca’s Enhertu, perform on these metrics?
• What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new metastatic HER2-positive breast cancer drug?

Product description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in February 2023.

Key companies: AstraZeneca, Roche / Genentech, Seagen, Puma Biotechnology.

Key drugs: Enhertu, Kadcyla, Perjeta, Herceptin, Phesgo, Tukysa, Nerlynx.